Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus
Solute carriers (SLCs) constitute the largest superfamily of membrane transporter proteins. These transporters, present in various SLC families, play a vital role in energy metabolism by facilitating the transport of diverse substances, including glucose, fatty acids, amino acids, nucleotides, and i...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-02-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221138352300357X |
| _version_ | 1827370491644477440 |
|---|---|
| author | Jiamei Le Yilong Chen Wei Yang Ligong Chen Jianping Ye |
| author_facet | Jiamei Le Yilong Chen Wei Yang Ligong Chen Jianping Ye |
| author_sort | Jiamei Le |
| collection | DOAJ |
| description | Solute carriers (SLCs) constitute the largest superfamily of membrane transporter proteins. These transporters, present in various SLC families, play a vital role in energy metabolism by facilitating the transport of diverse substances, including glucose, fatty acids, amino acids, nucleotides, and ions. They actively participate in the regulation of glucose metabolism at various steps, such as glucose uptake (e.g., SLC2A4/GLUT4), glucose reabsorption (e.g., SLC5A2/SGLT2), thermogenesis (e.g., SLC25A7/UCP-1), and ATP production (e.g., SLC25A4/ANT1 and SLC25A5/ANT2). The activities of these transporters contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). Notably, SLC5A2 has emerged as a valid drug target for T2DM due to its role in renal glucose reabsorption, leading to groundbreaking advancements in diabetes drug discovery. Alongside SLC5A2, multiple families of SLC transporters involved in the regulation of glucose homeostasis hold potential applications for T2DM therapy. SLCs also impact drug metabolism of diabetic medicines through gene polymorphisms, such as rosiglitazone (SLCO1B1/OATP1B1) and metformin (SLC22A1–3/OCT1–3 and SLC47A1, 2/MATE1, 2). By consolidating insights into the biological activities and clinical relevance of SLC transporters in T2DM, this review offers a comprehensive update on their roles in controlling glucose metabolism as potential drug targets. |
| first_indexed | 2024-03-08T10:16:10Z |
| format | Article |
| id | doaj.art-e8869c0351e341b4a5a6f86596e1a1cd |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-03-08T10:16:10Z |
| publishDate | 2024-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-e8869c0351e341b4a5a6f86596e1a1cd2024-01-29T04:15:12ZengElsevierActa Pharmaceutica Sinica B2211-38352024-02-01142437454Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitusJiamei Le0Yilong Chen1Wei Yang2Ligong Chen3Jianping Ye4Shanghai Key Laboratory of Molecular Imaging, Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai 201318, China; School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, ChinaSchool of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, ChinaMetabolic Disease Research Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, ChinaSchool of Pharmaceutical Sciences, Tsinghua University, Beijing 100084, ChinaMetabolic Disease Research Center, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou 450007, China; Research Center for Basic Medicine, Academy of Medical Sciences, Zhengzhou University, Zhengzhou 450052, China; Corresponding author.Solute carriers (SLCs) constitute the largest superfamily of membrane transporter proteins. These transporters, present in various SLC families, play a vital role in energy metabolism by facilitating the transport of diverse substances, including glucose, fatty acids, amino acids, nucleotides, and ions. They actively participate in the regulation of glucose metabolism at various steps, such as glucose uptake (e.g., SLC2A4/GLUT4), glucose reabsorption (e.g., SLC5A2/SGLT2), thermogenesis (e.g., SLC25A7/UCP-1), and ATP production (e.g., SLC25A4/ANT1 and SLC25A5/ANT2). The activities of these transporters contribute to the pathogenesis of type 2 diabetes mellitus (T2DM). Notably, SLC5A2 has emerged as a valid drug target for T2DM due to its role in renal glucose reabsorption, leading to groundbreaking advancements in diabetes drug discovery. Alongside SLC5A2, multiple families of SLC transporters involved in the regulation of glucose homeostasis hold potential applications for T2DM therapy. SLCs also impact drug metabolism of diabetic medicines through gene polymorphisms, such as rosiglitazone (SLCO1B1/OATP1B1) and metformin (SLC22A1–3/OCT1–3 and SLC47A1, 2/MATE1, 2). By consolidating insights into the biological activities and clinical relevance of SLC transporters in T2DM, this review offers a comprehensive update on their roles in controlling glucose metabolism as potential drug targets.http://www.sciencedirect.com/science/article/pii/S221138352300357XSolute carriers (SLCs)Energy metabolismATP productionType 2 diabetes mellitus (T2DM)Glucose homeostasisPolymorphisms |
| spellingShingle | Jiamei Le Yilong Chen Wei Yang Ligong Chen Jianping Ye Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus Acta Pharmaceutica Sinica B Solute carriers (SLCs) Energy metabolism ATP production Type 2 diabetes mellitus (T2DM) Glucose homeostasis Polymorphisms |
| title | Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus |
| title_full | Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus |
| title_fullStr | Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus |
| title_full_unstemmed | Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus |
| title_short | Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus |
| title_sort | metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus |
| topic | Solute carriers (SLCs) Energy metabolism ATP production Type 2 diabetes mellitus (T2DM) Glucose homeostasis Polymorphisms |
| url | http://www.sciencedirect.com/science/article/pii/S221138352300357X |
| work_keys_str_mv | AT jiameile metabolicbasisofsolutecarriertransportersintreatmentoftype2diabetesmellitus AT yilongchen metabolicbasisofsolutecarriertransportersintreatmentoftype2diabetesmellitus AT weiyang metabolicbasisofsolutecarriertransportersintreatmentoftype2diabetesmellitus AT ligongchen metabolicbasisofsolutecarriertransportersintreatmentoftype2diabetesmellitus AT jianpingye metabolicbasisofsolutecarriertransportersintreatmentoftype2diabetesmellitus |